1929519-13-0

Zelatriazin (TAK-041; NBI-1065846) is a potent and selective GPR139 agonist with an EC50 of 22 nM. Zelatriazin has the potential for the research of negative symptoms associated with schizophrenia[1].

[1] Reichard HA, et al. Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia [published online ahead of print, 2021 Jul 14]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00820. DOI:10.1021/acs.jmedchem.1c00820